Want to see CV full AI Analyst Report?
CV Stock Chart & Stats
$6.49
$0.12(1.85%)
At close: 4:00 PM EDT
$6.49
$0.12(1.85%)
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous Close$6.74
Volume83.71K
Average Volume (3M)45.47K
Market Cap
$328.76M
Enterprise Value$328.82
Total Cash (Recent Filing)$17.93M
Total Debt (Recent Filing)$788.00K
Price to Earnings (P/E)―
Beta-1.79
Next Earnings
Aug 13, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding49,963,585
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$15.57M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & Stable Gross MarginsSustained double‑digit top‑line growth with mid‑50s gross margins indicates solid unit economics and growing market adoption of capsule endoscopy. Over 2–6 months this supports scaling revenue without immediate margin erosion, improving the structural path to profitability if operating spend is controlled.
Operating Results Improved Toward BreakevenEBIT/EBITDA moving near break‑even reflects operating leverage and cost discipline, a durable indicator that core operations can approach self‑funding. If sustained, this structural improvement reduces reliance on external financing and supports long‑term cash flow durability.
Strengthened Board & Governance ContinuityAdding an experienced gastroenterologist and maintaining director/auditor continuity improves clinical oversight and corporate governance. This durable enhancement supports trial design, regulatory strategy and product development execution for next‑generation diagnostics over the coming months.
Bears Say
Very Large Net LossesNet margins well below zero show revenue currently cannot absorb non‑manufacturing costs and other expenses. Structurally, sustained heavy bottom‑line losses constrain reinvestment, force reliance on financing, and present long‑term viability risk absent meaningful margin expansion or revenue scale.
Persistent Negative Operating Cash FlowLarge, recurring operating cash outflows that grow year‑to‑year indicate structural cash burn. This persistent deficit erodes cash reserves and makes the company dependent on capital raises, increasing dilution risk and limiting capacity for sustained R&D or commercialization without new funding.
History Of Negative Equity And Potential DilutionPast negative equity and volatile returns show accumulated losses have weakened the capital base. Even with low reported debt, the structural need to rebuild equity through financings or convertibles risks dilution and may pressure strategic flexibility and investor confidence over the medium term.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $328.76M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on May 14, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.02.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Overvalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate is -0.13.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 49,963,585 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -11.575%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CV Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
108.43%
Trailing 12-Months
Company Description
CapsoVision, Inc.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
CV Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
8.63% Insiders
3.17% Mutual Funds
0.02% Other Institutional Investors
82.96% Public Companies and
Individual Investors